148 related articles for article (PubMed ID: 21471168)
1. Clinical and metabolic characteristics of acromegalic patients with high IGF1/normal GH levels during somatostatin analog treatment.
Matta M; Bongard V; Grunenwald S; Maiza JC; Bennet A; Caron P
Eur J Endocrinol; 2011 Jun; 164(6):885-9. PubMed ID: 21471168
[TBL] [Abstract][Full Text] [Related]
2. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
Valea A; Carsote M; Ghervan C; Georgescu C
J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
[TBL] [Abstract][Full Text] [Related]
3. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery.
Rubeck KZ; Madsen M; Andreasen CM; Fisker S; Frystyk J; Jørgensen JO
Eur J Endocrinol; 2010 Nov; 163(5):717-26. PubMed ID: 20813787
[TBL] [Abstract][Full Text] [Related]
4. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.
Howlett TA; Willis D; Walker G; Wass JA; Trainer PJ;
Clin Endocrinol (Oxf); 2013 Nov; 79(5):689-99. PubMed ID: 23574573
[TBL] [Abstract][Full Text] [Related]
5. The influence of age on the GH-IGF1 axis in patients with acromegaly.
Tanimoto K; Hizuka N; Fukuda I; Takano K; Hanafusa T
Eur J Endocrinol; 2008 Oct; 159(4):375-9. PubMed ID: 18653547
[TBL] [Abstract][Full Text] [Related]
6. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
[TBL] [Abstract][Full Text] [Related]
7. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.
Maison P; Tropeano AI; Macquin-Mavier I; Giustina A; Chanson P
J Clin Endocrinol Metab; 2007 May; 92(5):1743-7. PubMed ID: 17311857
[TBL] [Abstract][Full Text] [Related]
8. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.
Giustina A; Bonadonna S; Bugari G; Colao A; Cozzi R; Cannavo S; de Marinis L; Degli Uberti E; Bogazzi F; Mazziotti G; Minuto F; Montini M; Ghigo E
Eur J Endocrinol; 2009 Aug; 161(2):331-8. PubMed ID: 19465485
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.
Ayuk J; Stewart SE; Stewart PM; Sheppard MC
J Clin Endocrinol Metab; 2002 Sep; 87(9):4142-6. PubMed ID: 12213862
[TBL] [Abstract][Full Text] [Related]
10. Endothelial progenitor cells are reduced in acromegalic patients and can be restored by treatment with somatostatin analogs.
Fadini GP; Dassie F; Albiero M; Boscaro E; Albano I; Martini C; de Kreutzenberg SV; Agostini C; Avogaro A; Vettor R; Maffei P
J Clin Endocrinol Metab; 2014 Dec; 99(12):E2549-56. PubMed ID: 25144634
[TBL] [Abstract][Full Text] [Related]
11. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
12. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors.
Ronchi CL; Varca V; Beck-Peccoz P; Orsi E; Donadio F; Baccarelli A; Giavoli C; Ferrante E; Lania A; Spada A; Arosio M
J Clin Endocrinol Metab; 2006 Jan; 91(1):121-8. PubMed ID: 16263816
[TBL] [Abstract][Full Text] [Related]
13. D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly.
Kamenicky P; Dos Santos C; Espinosa C; Salenave S; Galland F; Le Bouc Y; Maison P; Bougnères P; Chanson P
Eur J Endocrinol; 2009 Aug; 161(2):231-5. PubMed ID: 19439509
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
De Marinis L; Bianchi A; Fusco A; Cimino V; Mormando M; Tilaro L; Mazziotti G; Pontecorvi A; Giustina A
Pituitary; 2007; 10(3):227-32. PubMed ID: 17484056
[TBL] [Abstract][Full Text] [Related]
15. Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.
Scacchi M; Carzaniga C; Vitale G; Fatti LM; Pecori Giraldi F; Andrioli M; Cattaneo A; Cavagnini F
J Endocrinol Invest; 2011 Oct; 34(9):e291-5. PubMed ID: 21697649
[TBL] [Abstract][Full Text] [Related]
16. Management of endocrine disease: GH excess: diagnosis and medical therapy.
Andersen M
Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
[TBL] [Abstract][Full Text] [Related]
17. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
18. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
19. Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients.
Christiansen Arlien-Søborg M; Trolle C; Alvarson E; Bæk A; Dal J; Otto Lunde Jørgensen J
Endocrine; 2017 Jun; 56(3):589-594. PubMed ID: 28260207
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.
Reimondo G; Bondanelli M; Ambrosio MR; Grimaldi F; Zaggia B; Zatelli MC; Allasino B; Laino F; Aroasio E; Termine A; Conton P; Paoletta A; Demenis E; Uberti ED; Terzolo M
Endocrine; 2014 Feb; 45(1):122-7. PubMed ID: 23794116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
